Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NNVC - NanoViricides, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: drkaz who wrote (9646)	1/2/2018 1:54:47 PM
From: HardToFind	Respond to of 12873

Debt holders are first in line for assets in liquidation so he'd get the rights to the technology. As the actual technology (IP) for the Cides resides within Diwan's privately held companies, and NNVC only holds exclusive licenses for pieces of the IP, NNVC's debt holders would not get rights to the underlying technology. They would get first dibs on the Shelton plant, equipment and such - and while that's worth something, it's not worth nearly as much as the IP would have been. I'm no a BK lawyer...but from what I know about the terms of the license and the BK process (never been through it personally) it seems that it really depends on how the BK were to go down. If the company refuses to pay a bondholder, but continues to pay TheraCour $25K a month (or whatever the terms require) to maintain the license, then the bondholder could very well assume the license to the technology as long as he is willing to keep paying $25K a month to maintain the terms of the licensing relationship.